Total Payments
$1.1M
2024 Payments
$77,352
Companies
25
Transactions
678
Medicare Patients
781
Medicare Billing
$64,206
Payment Breakdown by Category
Consulting$572,160 (52.9%)
Research$234,319 (21.7%)
Other$134,558 (12.5%)
Travel$126,610 (11.7%)
Food & Beverage$12,918 (1.2%)
Education$122.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $572,160 | 144 | 52.9% |
| Unspecified | $234,319 | 138 | 21.7% |
| Travel and Lodging | $126,610 | 177 | 11.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,288 | 19 | 7.4% |
| Honoraria | $54,270 | 10 | 5.0% |
| Food and Beverage | $12,918 | 186 | 1.2% |
| Education | $122.46 | 4 | 0.0% |
Payments by Type
General
$846,368
540 transactions
Research
$234,319
138 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $231,534 | 136 | $0 (2024) |
| UCB, Inc. | $176,748 | 116 | $0 (2024) |
| Novartis Pharma AG | $172,336 | 92 | $0 (2022) |
| PFIZER INC. | $132,462 | 63 | $0 (2024) |
| Eli Lilly and Company | $114,506 | 69 | $0 (2024) |
| UCB SA | $80,003 | 42 | $0 (2024) |
| GlaxoSmithKline, LLC. | $27,206 | 17 | $0 (2022) |
| AbbVie Inc. | $23,853 | 19 | $0 (2023) |
| Janssen Biotech, Inc. | $23,727 | 24 | $0 (2024) |
| UCB Biosciences Inc. | $21,113 | 13 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77,352 | 46 | UCB, Inc. ($37,911) |
| 2023 | $122,683 | 69 | Eli Lilly and Company ($28,331) |
| 2022 | $109,678 | 47 | UCB, Inc. ($41,046) |
| 2021 | $121,432 | 54 | PFIZER INC. ($34,893) |
| 2020 | $180,558 | 84 | Novartis Pharmaceuticals Corporation ($57,208) |
| 2019 | $189,189 | 153 | Novartis Pharma AG ($75,908) |
| 2018 | $139,479 | 123 | Novartis Pharma AG ($41,076) |
| 2017 | $140,315 | 102 | Novartis Pharmaceuticals Corporation ($43,591) |
All Payment Transactions
678 individual payment records from CMS Open Payments — Page 28 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/19/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Biological) | — | In-kind items and services | $458.40 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: DERMATOLOGY | ||||||
| 01/18/2017 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| 01/18/2017 | UCB, Inc. | Cimzia (Drug) | — | In-kind items and services | $420.00 | Research |
| Study: The Effect of Certolizumab Pegol on Radiographic Progression Over 4 Years of Treatment in Patients with Psoriatic Arthritis • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,010 | 17 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $20,855 | 10 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $17,269 | 3 |
| INVIGORATE-1 | Novartis Pharmaceuticals Corporation | $16,872 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $14,766 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $13,043 | 9 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE N | UCB, Inc. | $11,580 | 1 |
| ETANERCEPT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,310 | 9 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,425 | 3 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEK | UCB, Inc. | $6,900 | 1 |
| Publication support research related | Novartis Pharma AG | $5,684 | 6 |
| Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis on Certolizumab Pegol Treatment 2 Year Results from the Multicenter Phase 4 C-VIEW Study | UCB, Inc. | $4,600 | 1 |
| Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis on Certolizumab Pegol Treatment: 2 Year Results from the Multicenter Phase 4 C-VIEW Study | UCB, Inc. | $4,600 | 1 |
| Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation | UCB, Inc. | $4,500 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis | ABBVIE INC. | $3,600 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $3,498 | 2 |
| M16-098 | AbbVie, Inc. | $3,163 | 3 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS. | UCB, Inc. | $3,140 | 1 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active Axial Spondyloarthritis (AXSPA) without x-ray evi | UCB, Inc. | $3,140 | 3 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS | UCB, Inc. | $2,900 | 7 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE A | UCB, Inc. | $2,880 | 1 |
| MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF | UCB, Inc. | $2,800 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,483 | 4 |
| INVIGORATE | Novartis Pharmaceuticals Corporation | $2,409 | 1 |
| 4-Year Results from the RAPID-PsA Phase 3 Randomized Placebo-Controlled Trial of Certolizumab Pegol in Psoriatic Arthritis | UCB, Inc. | $2,300 | 1 |
| A 52-Week Randomized Placebo-Controlled Trial of Certolizumab in Non-Radiographic Axial Spondyloarthritis | UCB, Inc. | $2,300 | 1 |
| Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis | UCB, Inc. | $2,300 | 1 |
| Incidence and Prevalence of Axial Spondyloarthritis: Methodologic Challenges and Gaps in the Literature | UCB, Inc. | $2,300 | 1 |
| The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases | UCB, Inc. | $2,300 | 1 |
| TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,210 | 3 |
| Achievement of Remission is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage | UCB, Inc. | $1,640 | 2 |
| TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS AN ANALYSIS OF THREE US CLAIMS DATABASES | UCB, Inc. | $1,640 | 1 |
| TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES | UCB, Inc. | $1,640 | 1 |
| CAIN457P12301 | Novartis Pharmaceuticals Corporation | $1,357 | 1 |
| ACR 2020SEAM-PSA Treatment Effects Poster | Amgen Inc. | $1,192 | 1 |
| Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status | UCB, Inc. | $840.00 | 2 |
| A MULTICENTER, OPEN-LABEL, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH PSORIATIC ARTHRITIS | UCB, Inc. | $820.00 | 2 |
| MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOAR | UCB, Inc. | $820.00 | 2 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active | UCB, Inc. | $820.00 | 1 |
| Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs Post-Hoc Analysis from C-axSpAnd | UCB, Inc. | $820.00 | 1 |
| Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from C-axSpAnd | UCB, Inc. | $820.00 | 1 |
| SURPASS | Novartis Pharma AG | $525.00 | 1 |
| Additional Outcomes from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212) in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol | UCB, Inc. | $420.00 | 1 |
| Annual Diagnostic Prevalence of Ankylosing Spondylitis (AS) in the United States Using Medicare and MarketScan Data | UCB, Inc. | $420.00 | 1 |
| Annual Diagnostic Prevalence of Ankylosing Spondylitis AS in the United States Using Medicare and MarketScan Data | UCB, Inc. | $420.00 | 1 |
| Bimekizumab Long-Term Efficacy and Safety Over 96 Weeks in Patients With Ankylosing Spondylitis Interim Results From a Phase 2b Open-Label Extension Study | UCB, Inc. | $420.00 | 1 |
| Bimekizumab Long-Term Efficacy and Safety Over 96 Weeks in Patients With Ankylosing Spondylitis: Interim Results From a Phase 2b Open-Label Extension Study | UCB, Inc. | $420.00 | 1 |
| Bimekizumab Treatment is Associated with Improvements in Fatigue and Back Pain in Patients with Active Psoriatic Arthritis 48-Week Results from a Phase 2b Study | UCB, Inc. | $420.00 | 1 |
| Bimekizumab Treatment is Associated with Improvements in Fatigue and Back Pain in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study | UCB, Inc. | $420.00 | 1 |
| Certolizumab Pegol Provides Sustained Remission and Minimal Disease Activity in Patients with Psoriatic Arthritis Over 4 Years Treatment | UCB, Inc. | $420.00 | 1 |
| Certolizumab Pegol Versus Standard Care in Treating Non-Radiographic Axial Spondyloarthritis: Results for Asia-Pacific Versus Rest of the World from C-axSpAnd | UCB, Inc. | $420.00 | 1 |
| Do TNF Inhibitors Impact the Comorbidities and Extra-Articular Manifestations, and Thereby Alter the Natural History of Ankylosing Spondylitis? | UCB, Inc. | $420.00 | 1 |
| EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY | UCB, Inc. | $420.00 | 1 |
| EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY | UCB, Inc. | $420.00 | 1 |
| Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212) | UCB, Inc. | $420.00 | 1 |
| Efficacy and Safety of Bimekizumab in Ankylosing Spondylitis 48-Week Patient-Reported Outcomes from a Phase 2b, Randomised, Double-blind, Placebo-Controlled, Dose-Ranging Study | UCB, Inc. | $420.00 | 1 |
| Efficacy and Safety of Bimekizumab in Ankylosing Spondylitis: 48-Week Patient-Reported Outcomes from a Phase 2b, Randomised, Double-blind, Placebo-Controlled, Dose-Ranging Study | UCB, Inc. | $420.00 | 1 |
| The Effect of Certolizumab Pegol on Radiographic Progression Over 4 Years of Treatment in Patients with Psoriatic Arthritis | UCB, Inc. | $420.00 | 1 |
| Bimekizumab Treatment is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis 48-Week Results from a Phase 2b Study | UCB, Inc. | $400.00 | 1 |
| Bimekizumab Treatment is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study | UCB, Inc. | $400.00 | 1 |
| Do Anti-TNFs Impact the Comorbidities and Extra-Articular Manifestations, and Thereby Alter the Natural History of Ankylosing Spondylitis? | UCB, Inc. | $400.00 | 1 |
| PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ADULT ONSET ACTIVE AND PROGRESSIVE PSORIATIC ARTHRITIS (PSA) | UCB, Inc. | $400.00 | 1 |
| Does sex or body mass index impact response to therapy in psoriatic arthritis?: Results from a phas | Amgen Inc. | $243.31 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY OF SECUKINUMAB TO COMPARE 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO ARE RANDOMIZED TO DOSE ESCALATION AFTER NOT ACHIEVING INACTIVE DISEASE DURING AN INITIAL 16 WEEK OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG(ASLEAP) | Novartis Pharmaceuticals Corporation | $238.00 | 1 |
| Etanercept monotherapy in PsA | Amgen Inc. | $136.85 | 1 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $99.88 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 181 | 197 | $61,826 | $13,622 |
| 2022 | 3 | 166 | 188 | $53,824 | $14,644 |
| 2021 | 5 | 199 | 243 | $62,838 | $19,324 |
| 2020 | 6 | 235 | 282 | $61,062 | $16,616 |
Total Patients
781
Total Services
910
Medicare Billing
$64,206
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 124 | 138 | $38,796 | $9,413 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 31 | 33 | $13,630 | $2,395 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $4,811 | $944.44 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $4,589 | $870.33 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 123 | 143 | $36,946 | $9,867 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 25 | 27 | $10,434 | $3,222 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $6,444 | $1,556 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 122 | 160 | $36,302 | $12,059 | 33.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 31 | 31 | $10,589 | $3,204 | 30.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 16 | $5,197 | $1,806 | 34.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 18 | 23 | $6,979 | $1,564 | 22.4% |
| 20611 | Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | Facility | 2021 | 12 | 13 | $3,771 | $690.52 | 18.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 103 | 132 | $26,820 | $7,574 | 28.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 60 | 70 | $17,033 | $4,441 | 26.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 22 | 22 | $7,346 | $1,898 | 25.8% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 12 | 12 | $3,216 | $1,109 | 34.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 25 | 31 | $4,083 | $1,012 | 24.8% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Facility | 2020 | 13 | 15 | $2,564 | $580.82 | 22.7% |
About Dr. Atulya Deodhar, MD
Dr. Atulya Deodhar, MD is a Rheumatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558376053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Atulya Deodhar, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $77,352 received in 2024. These payments were reported across 678 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($572,160).
As a Medicare-enrolled provider, Deodhar has provided services to 781 Medicare beneficiaries, totaling 910 services with total Medicare billing of $64,206. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Portland, OR
- Active Since 07/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1558376053
Products in Payments
- COSENTYX (Biological) $170,822
- XELJANZ (Drug) $91,700
- Cimzia (Drug) $77,253
- AIN457F_COSENTYX_IMMUNOLOGY (Biological) $74,026
- TALTZ (Drug) $66,879
- Bimzelx (Biological) $50,557
- AIN457F (Biological) $45,762
- COSENTYX (Drug) $28,615
- ENBREL (Biological) $27,562
- TREMFYA (Drug) $24,056
- Tremfya (Drug) $16,714
- SECUKINUMAB_COSENTYX_DERMATOLOGY (Biological) $9,885
- Enbrel (Biological) $9,217
- COSENTYX_COSENTYX_DERMATOLOGY (Biological) $8,448
- CFZ533X (Biological) $5,306
- LUPKYNIS (Drug) $3,671
- RINVOQ (Biological) $3,600
- AIN457H (Biological) $3,495
- SECUKINUMAB (Biological) $2,623
- Rinvoq (Biological) $1,800
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Portland
Rosario Bonafede, Md, MD
Rheumatology — Payments: $238,645
Rheumatology $238,645
Dr. Andre Barkhuizen, M.d, M.D
Rheumatology — Payments: $25,592
Rheumatology $25,592
Cong-Qiu Chu, Md, MD
Rheumatology — Payments: $19,237
Rheumatology $19,237
Dr. Ajay Wanchu, Md, MD
Rheumatology — Payments: $3,910
Rheumatology $3,910
Dr. John Griffin, M.d, M.D
Rheumatology — Payments: $3,774
Rheumatology $3,774
Cailin Sibley, M.d, M.D
Rheumatology — Payments: $948.27
Rheumatology $948.27